First experience with direct factor Xa inhibition in patients with stable coronary disease: A pharmacokinetic and pharmacodynamic evaluation

Circulation

Volumn 105, Issue 20, 2002, Pages 2385-2391

  Dyke, Christopher K ^a   Becker, Richard C ^b   Kleiman, Neal S ^c   Hochman, Judith S ^d   Bovill, Edwin G ^e   Lincoff, A Michael ^f   Gerstenblith, Gary ^g   Dzavik, Vladimir ^h   Gardner, Laura H ^a   Hasselblad, Vic ^a   Zillman, Linda A ^a   Shimoto, Yoshimasa ^j   Robertson, Thomas L ⁱ   Kunitada, Satoshi ⁱ   Armstrong, Paul W ^h   Harrington, Robert A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^e UNIVERSITY OF VERMONT   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g JOHNS HOPKINS HOSPITAL   (United States)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ DAIICHI SANKYO CO   (Japan)

^j NONE

more..

Author keywords

Anticoagulants; Coronary disease; Pharmacokinetics; Thrombin; Thrombosis

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; CORRELATION COEFFICIENT; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ANTILIPEMIC AGENTS; ASPIRIN; COHORT STUDIES; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR XA; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INFUSIONS, INTRAVENOUS; INTERNATIONAL NORMALIZED RATIO; LINEAR MODELS; MALE; MIDDLE AGED; NAPHTHALENES; PARTIAL THROMBOPLASTIN TIME; PROPIONIC ACIDS; PROTHROMBIN TIME; TIME FACTORS;

EID: 0037150191     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000016351.12759.52     Document Type: Article

References (22)

1. Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
3. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
4. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina
5. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
6. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI IIB-ESSENCE meta-analysis
7. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation
8. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
9. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: PENTALYSE study
10. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa
11. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase
12. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats
13. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
14. DX 9065A, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies
15. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates
16. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft
17. Pharmacokinetics of the anticoagulant 14C-DX-9065a in the healthy male volunteer after a single intravenous dose
18. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers
19. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase
20. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
21. Low-molecular-weight heparins: Pharmacologic profile and product differentiation
22. Anti-Xa monitoring during treatment with low molecular weight heparin or danaparoid: Inter-assay variability